Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Cenobamato em adultos com convulsões de início focal (BLESS)

10 de novembro de 2026 atualizado por: Aziende Chimiche Riunite Angelini Francesco S.p.A

Cenobamato em adultos com convulsões de início focal: um estudo observacional multicêntrico do mundo real italiano

The BLESS Study contributes to filling this information gap by collecting data from the Italian clinical practice and the Compassionate Use Program, to better characterize the clinical profile of cenobamate describing its effectiveness, safety and tolerability in adult patients diagnosed with uncontrolled focal epilepsy despite the use of at least two antiepileptic medicinal products.

Visão geral do estudo

Descrição detalhada

The main objective of the study is to describe the effectiveness of adjunctive cenobamate treatment in adult patients with uncontrolled focal epilepsy in Italy, overall and according to age class, setting of cenobamate treatment, cenobamate final target daily dose prescribed, and number of concomitant Anti Seizure Medications (ASMs). This will be assessed by intra-patient percent change and achievement of a ≥50% reduction in the seizure frequency from the pre-treatment baseline over a period of 52 weeks.

Tipo de estudo

Observacional

Inscrição (Real)

936

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • Bari
      • Bari, Bari, Itália, 70124
        • Policlinico di Bari
    • Catanzaro
      • Catanzaro, Catanzaro, Itália, 88100
        • Università degli Studi di Catanzaro "Magna Graecia"
    • Isernia
      • Pozzilli, Isernia, Itália, 86077
        • IRCCS Neuromed
    • Pavia
      • Pavia, Pavia, Itália, 27100
        • Fondazione Istituto Neurologico Casimiro Mondino
    • Roma
      • Roma, Roma, Itália, 00128
        • Campus Bio-Medico
      • Roma, Roma, Itália, 00161
        • Policlinico Umberto I
    • Torino
      • Torino, Torino, Itália, 10153
        • Humanitas Gradenigo
    • Treviso
      • Conegliano, Treviso, Itália, 31015
        • Associazione La Nostra Famiglia - IRCCS Eugenio Medea
    • Udine
      • Udine, Udine, Itália, 33100
        • Azienda Sanitaria Universitaria (A.O.U.) Integrata
    • Vicenza
      • Vicenza, Vicenza, Itália, 36100
        • Ospedale San Bortolo

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 99 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra de Probabilidade

População do estudo

Adult patients diagnosed with focal epilepsy uncontrolled despite the use of at least two antiepileptic medicinal products, treated with adjunctive cenobamate in Italy. A single cohort of patients will be involved in the study, enrolling both subjects who initiated cenobamate treatment in accordance with the current clinical practice, and subjects previously included in the cenobamate Compassionate Use Programme in Italy, provided that they fulfil all of the eligibility criteria listed below

Descrição

Inclusion Criteria:

  • Age ≥18 years at the time of cenobamate treatment initiation
  • Male or female patients
  • Patients diagnosed with focal epilepsy uncontrolled despite a history of treatment with at least two antiepileptic medicinal products at the time of cenobamate treatment initiation in agreement with the Summary of Product Characteristics (SmPC)
  • Patients who at enrolment had received at least 12 weeks (titration period up to the initial recommended target dose of 200 mg daily completed) but no more than 52 weeks of cenobamate as adjunctive treatment of focal-onset seizures with or without secondary generalization
  • Patients with available retrospective data in medical charts and seizure diaries, including information about baseline seizure frequency prior to cenobamate treatment initiation
  • Patients who gave written informed consent to take part into the study and personal data processing consent following local regulation.
  • Patients who received adjunctive cenobamate for at least 12 weeks and discontinued permanently treatment before enrolment will also be included in the study-

Exclusion Criteria:

  • Patients diagnosed with familial short-QT syndrome
  • Patients affected by hypersensitivity to the active substance cenobamate or to any of the excipients (e.g., lactose monohydrate)
  • Patients with history of severe drug-induced hypersensitivity reaction, including (but not limited to) drug reaction with eosinophilia and systemic symptoms (DRESS), and Stevens Johnson syndrome
  • Patients enrolled in a clinical trial in which treatments for epilepsy are managed through a study protocol
  • Patient unable to read and write in Italian language and to autonomously fill in questionnaires and scales
  • Patients with a known pregnancy or who are breast-feeding from cenobamate treatment initiation till enrolment visit.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: OTHER
  • Perspectivas de Tempo: PROSPECTIVE

Coortes e Intervenções

Grupo / Coorte
Adult patients diagnosed treated with adjunctive cenobamate in Italy.

Adult patients diagnosed with focal epilepsy uncontrolled despite the use of at least two antiepileptic medicinal products, treated with adjunctive cenobamate in Italy.

A single cohort of patients will be involved in the study, enrolling both subjects who initiated cenobamate treatment in accordance with the current clinical practice, and subjects previously included in the cenobamate Compassionate Use Programme in Italy, provided that they fulfil all of the eligibility criteria listed below

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Absolute frequency of patients achieving a 50 % or greater reduction in the seizure frequency (overall)
Prazo: 12, 24 and 52 weeks of cenobamate treatment initiation

Seizure frequency during the baseline and post-baseline assessments was calculated by summing the total number of seizures (all types of seizures) reported in each considered period and dividing by the duration of that period (number of days), excluding days with no available diary data, and multiplying by 28 to normalize to a monthly rate ("monthly seizure frequency").

12, 24 and 52 weeks of cenobamate treatment initiation
Relative frequency of patients achieving a ≥50% (50% or greater) reduction in the seizure frequency (overall)
Prazo: 12, 24 and 52 weeks of cenobamate treatment initiation

Seizure frequency during the baseline and post-baseline assessments was calculated by summing the total number of seizures (all types of seizures) reported in each considered period and dividing by the duration of that period (number of days), excluding days with no available diary data, and multiplying by 28 to normalize to a monthly rate ("monthly seizure frequency").

12, 24 and 52 weeks of cenobamate treatment initiation
Intra-patient percent change in the seizure frequency (overall)
Prazo: 12, 24 and 52 weeks of cenobamate treatment initiation

Intra-patient percent change from baseline will be defined as [(monthly seizure frequency at post-baseline assessments - monthly seizure frequency at baseline), divided by the monthly seizure frequency at baseline] multiplied by 100.

12, 24 and 52 weeks of cenobamate treatment initiation
Absolute frequency of patients achieving a 50 % or greater reduction in the seizure (stratified)
Prazo: 12, 24 and 52 weeks of cenobamate treatment initiation

Seizure frequency during the baseline and post-baseline assessments was calculated by summing the total number of seizures (all types of seizures) reported in each considered period and dividing by the duration of that period (number of days), excluding days with no available diary data, and multiplying by 28 to normalize to a monthly rate ("monthly seizure frequency").

Population will be stratified according to the following:

  • Age class of patient at the time of cenobamate treatment initiation (i.e., <65 years; ≥65 years).
  • Setting of cenobamate treatment initiation (i.e., CUP; current clinical practice).
  • Cenobamate final target daily dose prescribed (i.e., 200 mg; >200 mg).
  • Number of ASMs concomitant with cenobamate (i.e., ≤2 ASMs; >2 ASMs).
12, 24 and 52 weeks of cenobamate treatment initiation
Relative frequency of patients achieving a ≥50% (50% or greater) reduction in the seizure frequency (stratified)
Prazo: 12, 24 and 52 weeks of cenobamate treatment initiation

Seizure frequency during the baseline and post-baseline assessments was calculated by summing the total number of seizures (all types of seizures) reported in each considered period and dividing by the duration of that period (number of days), excluding days with no available diary data, and multiplying by 28 to normalize to a monthly rate ("monthly seizure frequency").

Population will be stratified according to the following:

  • Age class of patient at the time of cenobamate treatment initiation (i.e., <65 years; ≥65 years).
  • Setting of cenobamate treatment initiation (i.e., CUP; current clinical practice).
  • Cenobamate final target daily dose prescribed (i.e., 200 mg; >200 mg).
  • Number of ASMs concomitant with cenobamate (i.e., ≤2 ASMs; >2 ASMs).
12, 24 and 52 weeks of cenobamate treatment initiation
Intra-patient percent change in the seizure frequency (stratified)
Prazo: 12, 24 and 52 weeks of cenobamate treatment initiation

Intra-patient percent change from baseline will be defined as [(monthly seizure frequency at post-baseline assessments - monthly seizure frequency at baseline), divided by the monthly seizure frequency at baseline] multiplied by 100.

Population will be stratified according to the following:

  • Age class of patient at the time of cenobamate treatment initiation (i.e., <65 years; ≥65 years).
  • Setting of cenobamate treatment initiation (i.e., CUP; current clinical practice).
  • Cenobamate final target daily dose prescribed (i.e., 200 mg; >200 mg).
  • Number of ASMs concomitant with cenobamate (i.e., ≤2 ASMs; >2 ASMs).
12, 24 and 52 weeks of cenobamate treatment initiation

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Absolute frequency of patients achieving a ≥50%/≥75%/≥90%/=100% sustained reduction in the seizure frequency
Prazo: 24 and 52 weeks of cenobamate treatment initiation.

Sustained seizure frequency reduction will be defined as a ≥50%/≥75%/≥90%/=100% reduction in baseline seizure frequency achieved at 12 weeks of cenobamate treatment initiation, that continues (is sustained) without interruption and without cenobamate permanent discontinuation through the observation period until 24 and 52 weeks of cenobamate treatment initiation, respectively.

24 and 52 weeks of cenobamate treatment initiation.
Absolute frequency of patients achieving a ≥75%/≥90%/=100% reduction in the seizure frequency
Prazo: 12, 24 and 52 weeks of cenobamate treatment initiation.

Seizure frequency reduction will be defined as a ≥75%/≥90%/=100% reduction in baseline seizure frequency achieved at 12, 24 and 52 weeks of cenobamate treatment initiation, respectively.

12, 24 and 52 weeks of cenobamate treatment initiation.
Relative frequencies of patients achieving a ≥50%/≥75%/≥90%/=100% sustained reduction in the seizure frequency
Prazo: 24 and 52 weeks of cenobamate treatment initiation.

Sustained seizure frequency reduction will be defined as a ≥50%/≥75%/≥90%/=100% reduction in baseline seizure frequency achieved at 12 weeks of cenobamate treatment initiation, that continues (is sustained) without interruption and without cenobamate permanent discontinuation through the observation period until 24 and 52 weeks of cenobamate treatment initiation, respectively

24 and 52 weeks of cenobamate treatment initiation.
Relative frequencies of patients achieving a ≥75%/≥90%/=100% reduction in the seizure frequency
Prazo: 12, 24 and 52 weeks of cenobamate treatment initiation.

Seizure frequency reduction will be defined as a ≥75%/≥90%/=100% reduction in baseline seizure frequency achieved at 12, 24 and 52 weeks of cenobamate treatment initiation.

12, 24 and 52 weeks of cenobamate treatment initiation.
Absolute frequency of patients with at least one AE
Prazo: Through study completion, an average of 1 year

Absolute frequency of patients treated with cenobamate who experienced at least one AE during the applicable observation period

Through study completion, an average of 1 year
Relative frequency of patients with at least one AE
Prazo: Through study completion, an average of 1 year

Relative frequency of patients treated with cenobamate who experienced at least one AE during the applicable observation period

Through study completion, an average of 1 year
Absolute frequency of patients with at least one ADR
Prazo: Through study completion, an average of 1 year

Absolute frequency of patients treated with cenobamate who experienced at least one ADR during the applicable observation period

Through study completion, an average of 1 year
Relative frequency of patients with at least one ADR
Prazo: Through study completion, an average of 1 year

Relative frequency of patients treated with cenobamate who experienced at least one ADR during the applicable observation period

Through study completion, an average of 1 year
Absolute frequency of patients treated with at least one SAE
Prazo: Through study completion, an average of 1 year

Absolute frequency of patients treated with at least one SAE during the applicable observation period

Through study completion, an average of 1 year
Relative frequency of patients treated with at least one SAE
Prazo: Through study completion, an average of 1 year

Relative frequency of patients treated with at least one SAE during the applicable observation period

Through study completion, an average of 1 year
Health-Related Quality of life (HRQoL)
Prazo: 12, 24 and 52 weeks

The Health-Related Quality of life (HRQoL) of patients will be assessed by means of the 31-item Quality Of Life In Epilepsy inventory (QOLIE-31).

The 31-item Quality Of Life In Epilepsy inventory (QOLIE-31) is a patient self-reported instrument that contains 31 items grouped in seven multi-item scales ( "seizure worry", "overall QoL", "emotional well-being", "energy fatigue", "cognitive functioning", "medication effects" and "social functioning"). Different items in the QOLIE-31 have different ranges of precoded numeric values, so the scoring procedure requires conversion from raw, precoded numeric values to scores of 0-100 points, with higher scores reflecting better quality of life. The QOLIE-31 overall score is calculated by summing the product of each scale score times its weight and summing over all scales, according to the instructions obtained from copyright holders.

12, 24 and 52 weeks
Patient Global functioning (CGI-S)
Prazo: 12, 24 and 52 weeks

The patient global functioning will be assessed by means of the Clinical Global Impression (CGI) Scales. The Early Clinical Drug Evaluation Program (ECDEU) version of the CGI is a 3-item clinician rated scale that measures illness severity (CGI-S), global improvement or change (CGI-I) and treatment response (efficacy index: CGI-E).

The CGI-S score ranges from 1 (normal) through to 7 (amongst the most severely ill patients).

The calculation of the scores will be performed according to the instructions obtained from copyright holders.

12, 24 and 52 weeks
Patient Global functioning (CGI-I)
Prazo: 12, 24 and 52 weeks

The patient global functioning will be assessed by means of the Clinical Global Impression (CGI) Scales. The Early Clinical Drug Evaluation Program (ECDEU) version of the CGI is a 3-item clinician rated scale that measures illness severity (CGI-S), global improvement or change (CGI-I) and treatment response (efficacy index: CGI-E).

The CGI-I score ranges from 1 (very much improved) through to 7 (very much worse).

The calculation of the scores will be performed according to the instructions obtained from copyright holders.

12, 24 and 52 weeks
Patient Global functioning (CGI-E)
Prazo: 12, 24 and 52 weeks

The patient global functioning will be assessed by means of the Clinical Global Impression (CGI) Scales. The Early Clinical Drug Evaluation Program (ECDEU) version of the CGI is a 3-item clinician rated scale that measures illness severity (CGI-S), global improvement or change (CGI-I) and treatment response (efficacy index: CGI-E).

The CGI-E score should take account of both therapeutic effect and tolerance, and ranges from 0 (marked improvement and no toxicity) and 4 (unchanged or worse and toxicity outweigh the therapeutic effects). Each component of the CGI is rated separately; the instrument does not yield a global score.

The calculation of the scores will be performed according to the instructions obtained from copyright holders.

12, 24 and 52 weeks
Daytime Sleepiness
Prazo: 12, 24 and 52 weeks

Daytime Sleepiness will be assessed by means of the Epworth Sleepiness Scale (ESS). The ESS is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different daily activities. The ESS score can range from 0 to 24. The higher the ESS score, the higher that person Average Sleep Propensity in Daily Life (ASP), or their daytime sleepiness across a wide range of activities in their daily lives.

12, 24 and 52 weeks
Hospital Anxiety and Depression
Prazo: 12, 24 and 52 weeks

Anxiety and depression symptoms will be assessed by means of the the Hospital Anxiety and Depression Scale (HADS). This is a patient self-reported instrument consisting of 14 items that provide scores on two specific subscales: "Anxiety" subscale (HADS-A, 7 items) and "Depression" subscale (HADS-D, 7 items).

All items were scored on a 4-point Likert scale from 0 ("never") to 3 ("almost every day") referring to overt symptoms within the last week. Total scores range from 0 to 21 points for each subscale, with higher scores indicating higher levels of symptoms.

12, 24 and 52 weeks
Retention with cenobamate
Prazo: 52 weeks

Retention with cenobamate will be assessed by calculating the frequency of patients still on treatment with cenobamate at 52 weeks of treatment initiation.

52 weeks

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

24 de janeiro de 2023

Conclusão Primária (Real)

30 de dezembro de 2025

Conclusão do estudo (Real)

21 de outubro de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

26 de abril de 2023

Enviado pela primeira vez que atendeu aos critérios de CQ

5 de maio de 2023

Primeira postagem (Real)

16 de maio de 2023

Atualizações de registro de estudo

Última Atualização Postada (Real)

13 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

10 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever